Sumitomo Dainippon Pharma Co. Ltd. failed to reach an agreement on terms to acquire stem cell technology company Cynata Therapeutics Ltd.
The parties have withdrawn from the acquisition discussions after failing to arrive at a deal.
The Osaka, Japan-based drugmaker previously offered to acquire Australia's Cynata for A$2 per share in cash under a scheme of agreement.
The offer, made in July, valued the stem cell and regenerative medicines company at about A$203.8 million.
Sumitomo manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics and other products.
Cynata, which offers a mesenchymal stem cell technology, is developing its lead product candidate CYP-001 as a treatment for graft versus host disease.